1-42 of 42
Keywords: Parkinson's disease
Close
Follow your search
Access your saved searches in your account

Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Articles
Biochem J (2021) 478 (5): 997–1008.
Published: 04 March 2021
... its direct involvement in the regulation of the activity of an important tumor suppressor p53 in the Mdm2/Mdmx-p53 pathway. Mutations in the RPS15 gene encoding rp uS19 are linked to diseases (Diamond Blackfan anemia, chronic lymphocytic leukemia and Parkinson's disease) caused either by defects in...
Articles
Biochem J (2020) 477 (6): 1109–1122.
Published: 23 March 2020
...Upasana Ganguly; Anindita Banerjee; Sankha Shubhra Chakrabarti; Upinder Kaur; Oishimaya Sen; Roberto Cappai; Sasanka Chakrabarti The toxicity of accumulated α-synuclein plays a key role in the neurodegeneration of Parkinson's disease (PD). This study has demonstrated that iron in varying...
Includes: Supplementary data
Articles
Biochem J (2019) 476 (3): 559–579.
Published: 08 February 2019
...Emmanouela Leandrou; Eliana Markidi; Anna Memou; Katerina Melachroinou; Elisa Greggio; Hardy J. Rideout The Parkinson's disease (PD) protein leucine-rich repeat kinase 2 (LRRK2) exists as a mixture of monomeric and dimeric species, with its kinase activity highly concentrated in the dimeric...
Includes: Supplementary data
Articles
Biochem J (2019) 476 (2): 261–274.
Published: 25 January 2019
... involved in the hydrolysis of glucosylceramide. The discovery of an association between mutations in GBA1 and the development of synucleinopathies, including Parkinson disease, has directed attention to glucocerebrosidase as a potential therapeutic target for different synucleinopathies. These findings...
Articles
Biochem J (2018) 475 (7): 1271–1293.
Published: 09 April 2018
... to develop Parkinson's disease (PD). LRRK2 kinase activity is increased in several pathogenic mutations (N1437H, R1441C/G/H, Y1699C, G2019S), implicating hyperphosphorylation of a substrate in the pathogenesis of the disease. Identification of the downstream targets of LRRK2 is a crucial endeavor in...
Includes: Supplementary data
Articles
Biochem J (2018) 475 (1): 185–189.
Published: 05 January 2018
... (LRRK2) is a Ser/Thr kinase linked to familial and sporadic cases of Parkinson's disease (PD). Recent work established that multiple Rab GTPases are physiological substrates of LRRK2, with Rab10 in particular emerging as a human substrate whose site-specific phosphorylation mirrors hyperactive LRRK2...
Articles
Biochem J (2018) 475 (1): 1–22.
Published: 02 January 2018
... kinase 2) protein kinase predispose to Parkinson's disease, suggesting that LRRK2 inhibitors might have therapeutic benefit. Recent work has revealed that LRRK2 phosphorylates a subgroup of 14 Rab proteins, including Rab10, at a specific residue located at the centre of its effector-binding switch-II...
Includes: Supplementary data
Articles
Biochem J (2018) 475 (1): 23–44.
Published: 02 January 2018
...) 2018 This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution License 4.0 (CC BY) . biomarkers diagnostics leucine-rich repeat kinase neutrophils Parkinson's disease Rab10...
Includes: Supplementary data
Articles
Biochem J (2017) 474 (18): 3075–3086.
Published: 31 August 2017
...Nikhil Panicker; Valina L. Dawson; Ted M. Dawson Monogenetic, familial forms of Parkinson's disease (PD) only account for 5–10% of the total number of PD cases, but analysis of the genes involved therein is invaluable to understanding PD-associated neurodegenerative signaling. One such gene, parkin...
Articles
Biochem J (2017) 474 (9): 1547–1558.
Published: 24 April 2017
...Iakov N. Rudenko; Alice Kaganovich; Rebekah G. Langston; Aleksandra Beilina; Kelechi Ndukwe; Ravindran Kumaran; Allissa A. Dillman; Ruth Chia; Mark R. Cookson Autosomal dominant mutations in leucine-rich repeat kinase 2 ( LRRK2 ) are associated with Parkinson's disease (PD). Most pathogenic LRRK2...
Includes: Supplementary data
Articles
Biochem J (2017) 474 (9): 1439–1451.
Published: 13 April 2017
...Helen Walden; Miratul M.K. Muqit Biochemical alterations found in the brains of Parkinson's disease (PD) patients indicate that cellular stress is a major driver of dopaminergic neuronal loss. Oxidative stress, mitochondrial dysfunction, and ER stress lead to impairment of the homeostatic...
Articles
Biochem J (2017) 474 (7): 1273–1287.
Published: 23 March 2017
...Loes M. Stevers; Rens M.J.M. de Vries; Richard G. Doveston; Lech-Gustav Milroy; Luc Brunsveld; Christian Ottmann Binding of 14-3-3 proteins to leucine-rich repeat protein kinase 2 (LRRK2) is known to be impaired by many Parkinson's disease (PD)-relevant mutations. Abrogation of this interaction is...
Includes: Supplementary data
Articles
Biochem J (2016) 473 (18): 2757–2762.
Published: 12 September 2016
...Patrick A. Eyers Protein kinases catalyse the addition of phosphate groups to Ser/Thr and Tyr residues in cognate substrates and are mutated or hyperactive in a variety of diseases, making them important targets for rationally designed drugs. A good example is the Parkinson's disease-associated...
Articles
Biochem J (2016) 473 (17): 2671–2685.
Published: 30 August 2016
... Parkinson's disease. Recent work has revealed that LRRK2 directly phosphorylates a conserved threonine/serine residue in the effector-binding switch-II motif of a number of Rab GTPase proteins, including Rab10. Here we describe a facile and robust method to assess phosphorylation of endogenous Rab10 in mouse...
Includes: Supplementary data
Articles
Biochem J (2015) 470 (3): e21–e24.
Published: 04 September 2015
...Heather L. Melrose Pathogenic mutations and risk variants in LRRK2 (leucine-rich repeat kinase 2) represent the most common genetic cause of familial and sporadic PD (Parkinson's disease). LRRK2 protein is widely expressed throughout the brain and the periphery. Structurally, LRRK2 contains several...
Articles
Biochem J (2015) 469 (1): 107–120.
Published: 19 June 2015
...Jing Zhao; Tyler P. Molitor; J. William Langston; R. Jeremy Nichols Activating mutations in the leucine rich repeat protein kinase 2 ( LRRK2 ) gene are the most common cause of inherited Parkinson's disease (PD). LRRK2 is phosphorylated on a cluster of phosphosites including Ser 910 , Ser 935 , Ser...
Articles
Biochem J (2015) 467 (2): 303–310.
Published: 02 April 2015
... the development of autosomal recessive early-onset Parkinson's disease (PD) [ 10 ]. Remarkably, the function of DJ1 has been linked with those of phosphatase and tensin homologue deleted on chromosome 10 (PTEN)-induced protein kinase-1 (Pink1) and Parkin, two proteins also found mutated in autosomal...
Articles
Biochem J (2015) 465 (1): 139–147.
Published: 12 December 2014
...Susanne Terheyden; Franz Y. Ho; Bernd K. Gilsbach; Alfred Wittinghofer; Arjan Kortholt Mutations in leucine-rich-repeat kinase 2 (LRRK2) are the most frequent cause of late-onset Parkinson's disease (PD). LRRK2 belongs to the Roco family of proteins which share a conserved Ras-like G-domain (Roc...
Includes: Supplementary data
Articles
Biochem J (2014) 460 (3): e1–e3.
Published: 29 May 2014
...Gary S. Shaw The dysfunction of the E3 ubiquitin ligase Parkin is a key contributor to the development of early-onset Parkinson's disease. Parkin is responsible for the labelling of outer mitochondrial membrane proteins with the small modifier protein ubiquitin in response to oxidative stress. This...
Articles
Biochem J (2014) 460 (1): 127–141.
Published: 25 April 2014
...Agne Kazlauskaite; Chandana Kondapalli; Robert Gourlay; David G. Campbell; Maria Stella Ritorto; Kay Hofmann; Dario R. Alessi; Axel Knebel; Matthias Trost; Miratul M. K. Muqit We have previously reported that the Parkinson's disease-associated kinase PINK1 (PTEN-induced putative kinase 1) is...
Includes: Supplementary data
Articles
Biochem J (2013) 456 (1): 119–128.
Published: 24 October 2013
... 935 , Ser 955 and Ser 973 , is important for PD (Parkinson's disease) pathogenesis as several PD-linked LRRK2 mutants are dephosphorylated at these sites. LRRK2 is also dephosphorylated in cells after pharmacological inhibition of its kinase activity, which is currently proposed as a strategy for...
Includes: Supplementary data
Articles
Biochem J (2013) 455 (3): 295–306.
Published: 10 October 2013
...Stijn De Graeve; Sarah Marinelli; Frank Stolz; Jelle Hendrix; Jurgen Vandamme; Yves Engelborghs; Patrick Van Dijck; Johan M. Thevelein Accumulation of aggregated forms of αSyn (α-synuclein) into Lewy bodies is a known hallmark associated with neuronal cell death in Parkinson's disease. When...
Articles
Biochem J (2013) 453 (1): 101–113.
Published: 13 June 2013
... major cause of PD (Parkinson's disease). Several antibodies against LRRK2 have been developed, but results using these polyclonal antibodies have varied widely leading to conflicting conclusions. To address this challenge, the Michael J. Fox Foundation for Parkinson's Research generated a number of...
Includes: Supplementary data
Articles
Biochem J (2013) 450 (2): 265–274.
Published: 15 February 2013
... either of these authors (email vprado@robarts.ca or mprado@robarts.ca ). 1 11 2012 15 11 2012 22 11 2012 © The Authors Journal compilation © 2013 Biochemical Society 2013 Alzheimer’s disease heart failure Parkinson’s disease sepsis synaptic vesicle vascular dementia...
Includes: Multimedia, Supplementary data
Articles
Biochem J (2013) 450 (1): 47–53.
Published: 24 January 2013
... belong to the P 5 -ATPase group have been identified in humans. Mutations of the human gene ATP13A2 underlie a form of PD (Parkinson's disease). Previous studies have suggested a relation between polyamines and P 5B -ATPases. We have recently shown that the cytotoxicity induced by the polyamine analogue...
Includes: Supplementary data
Articles
Biochem J (2012) 443 (3): 719–726.
Published: 16 April 2012
...María Soledad Celej; Rabia Sarroukh; Erik Goormaghtigh; Gerardo D. Fidelio; Jean-Marie Ruysschaert; Vincent Raussens Parkinson's disease is an age-related movement disorder characterized by the presence in the mid-brain of amyloid deposits of the 140-amino-acid protein AS (α-synuclein). AS...
Articles
Biochem J (2012) 441 (3): 987–998.
Published: 16 January 2012
...Genta Ito; Takeshi Iwatsubo Mutations in the LRRK2 (leucine-rich repeat kinase 2) gene have been identified in PARK8, a major form of autosomal-dominantly inherited familial Parkinson's disease, although the biochemical properties of LRRK2 are not fully understood. It has been proposed that LRRK2...
Includes: Supplementary data
Articles
Biochem J (2011) 438 (3): 415–426.
Published: 26 August 2011
... computer simulation integrative biology molecular dynamics Parkinson's disease Amyloid-related diseases comprise a group of several dozen pathologies. The most common among the human amyloid-related diseases are AD (Alzheimer's disease), PD (Parkinson's disease) and T2DM (Type 2 diabetes...
Includes: Multimedia, Supplementary data
Articles
Biochem J (2011) 436 (1): 145–155.
Published: 27 April 2011
... expression is significantly elevated in a number of cancers, and we have previously demonstrated that NNMT expression is significantly increased in the brains of patients who have died of Parkinson's disease. To investigate the cellular effects of NNMT overexpression, we overexpressed NNMT in the SH-SY5Y...
Articles
Biochem J (2010) 430 (3): e5–e6.
Published: 27 August 2010
...Iakov N. Rudenko; Mark R. Cookson Mutations in LRRK2 (leucine-rich repeat kinase 2) are the most common cause of familial PD (Parkinson’s disease). Mutations that cause PD are found in either the GTPase or kinase domains of LRRK2 or an intervening sequence called the COR [C-terminus of ROC (Ras of...
Articles
Biochem J (2010) 430 (3): 393–404.
Published: 27 August 2010
...R. Jeremy Nichols; Nicolas Dzamko; Nicholas A. Morrice; David G. Campbell; Maria Deak; Alban Ordureau; Thomas Macartney; Youren Tong; Jie Shen; Alan R. Prescott; Dario R. Alessi LRRK2 (leucine-rich repeat protein kinase 2) is mutated in a significant number of Parkinson's disease patients, but...
Includes: Supplementary data
Articles
Biochem J (2010) 430 (3): 405–413.
Published: 27 August 2010
...Nicolas Dzamko; Maria Deak; Faycal Hentati; Alastair D. Reith; Alan R. Prescott; Dario R. Alessi; R. Jeremy Nichols LRRK2 (leucine-rich repeat protein kinase 2) is mutated in a significant number of Parkinson's disease patients. Since a common mutation that replaces Gly 2019 with a serine residue...
Includes: Supplementary data
Articles
Biochem J (2009) 424 (1): 47–60.
Published: 23 October 2009
...R. Jeremy Nichols; Nicolas Dzamko; Jessica E. Hutti; Lewis C. Cantley; Maria Deak; Jennifer Moran; Paul Bamborough; Alastair D. Reith; Dario R. Alessi The LRRK2 (leucine-rich repeat protein kinase-2) is mutated in a significant number of Parkinson's disease patients, but little is known about its...
Includes: Supplementary data
Articles
Biochem J (2009) 424 (1): e1–e3.
Published: 23 October 2009
...Geou-Yarh Liou; Kathleen A. Gallo Some 5 years ago, it was first discovered that mutations in the gene encoding LRRK2 (leucine-rich repeat protein kinase 2) are tightly linked with a subset of familial PD (Parkinson's disease). Before this genetic association, LRRK2 had never been investigated...
Articles
Biochem J (2009) 418 (2): 311–323.
Published: 11 February 2009
...Jung-Ho Lee; In-Hwan Lee; Young-Jun Choe; Sungsoo Kang; Hui Young Kim; Wei-Ping Gai; Ji-Sook Hahn; Seung R. Paik α-Synuclein is a pathological component of PD (Parkinson's disease) by participating in Lewy body formation. JC-1 (5,5′,6,6′-tetrachloro-1,1,3,3′-tetraethylbenzimidazolyl carbocyanine...
Articles
Biochem J (2008) 413 (1): 1–13.
Published: 12 June 2008
...Philip A. Robinson Parkinson's disease (PD), the second most common age-related neurodegenerative disease, results in abnormalities in motor functioning. Many fundamental questions regarding its aetiology remain unanswered. Pathologically, it is not until 70–80% of the dopaminergic neurons from the...
Articles
Biochem J (2006) 393 (1): 343–349.
Published: 12 December 2005
... The Biochemical Society, London 2006 lipid–protein adduct neurodegenerative disorder Parkinson's disease peroxynitrite α-synuclein nitration Wild-type α-syn (α-synuclein) is a major component of Lewy bodies (LBs) in sporadic Parkinson's disease (PD). A number of neurodegenerative...
Articles
Biochem J (2004) 378 (3): 975–982.
Published: 15 March 2004
... 11 2003 The Biochemical Society, London ©2004 2004 calcium channel nerve growth factor non-transferrin-bound iron Parkinson's disease PC12 cell transient receptor potential canonical 6 (TRPC6) Abbreviations used: DAG, diacylglycerol; DMEM, Dulbecco's modified Eagle's medium...
Articles
Biochem J (2004) 378 (2): 435–447.
Published: 01 March 2004
... Cu,Zn-superoxide dismutase (SOD1) electron spin resonance (ESR) neurodegenerative disease Parkinson's disease spin trapping α-synuclein Abbreviations used: DLPC, 1,2-dilauryl- sn -glycero-3-phosphatidylcholine; DMPO, 5,5´-dimethyl-1-pyrroline N -oxide; DTPA, diethylenetriaminepenta...
Articles
Biochem J (2003) 373 (1): 25–32.
Published: 01 July 2003
...Venugopalan D. NAIR; C. Warren OLANOW; Stuart C. SEALFON Whereas dopamine agonists are known to provide symptomatic benefits for Parkinson's disease, recent clinical trials suggest that they might also be neuroprotective. Laboratory studies demonstrate that dopamine agonists can provide...
Articles
Biochem J (2003) 371 (1): 151–164.
Published: 01 April 2003
...Shasi V. KALIVENDI; Srigiridhar KOTAMRAJU; Sonya CUNNINGHAM; Tiesong SHANG; Cecilia J. HILLARD; B. KALYANARAMAN 1-Methyl-4-phenylpyridinium (MPP + ) is a neurotoxin used in cellular models of Parkinson's Disease. Although intracellular iron plays a crucial role in MPP + -induced apoptosis, the...
Articles
Biochem J (2001) 357 (3): 881–886.
Published: 25 July 2001
... Parkinson's disease transferrin Abbreviations used: NGF, nerve growth factor; nNOS, neuronal nitric oxide synthase; NTA, nitrilotriacetate; NTBI, non-transferrin-bound iron; PSS, physiological saline solution; TBI, transferrin-bound iron. Biochem. J. (2001) 357, 881 886 (Printed in Great Britain...